Q1 2024 results - Tuesday, April 23, 2024
Media release:
English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB) | Français (PDF 0.4 MB)
Interim financial report (PDF 0.4 MB)
Download the podcast (MP3 30 MB)
Download the interactive presentation (PDF 6.0 MB)
Novartis Q1 2024 impact and sustainability update (PDF 1.4 MB)
| Key figures1 | Continuing operations2 | ||
|---|---|---|---|
| Q1 2024 (USD m) | Q1 2023 (USD m) | % change (USD/cc) | |
| Net sales | 11,829 | 10,798 | 10 (cc: 11) |
| Operating income | 3,373 | 2,618 | 29 (cc: 39) |
| Net income | 2,688 | 2,150 | 25 (cc: 37) |
| EPS (USD) | 1.31 | 1.02 | 28 (cc: 41) |
| Free cash flow | 2,038 | 2,684 | -24 |
Core | |||
| Operating income | 4,537 | 3,906 | 16 (cc: 22) |
| Net income | 3,681 | 3,233 | 14 (cc: 19) |
| EPS (USD) | 1.80 | 1.54 | 17 (cc: 23) |
- Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 34 of the Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.
- As defined on page 26 of the Interim Financial Report, Continuing operations include the retained business activities of Novartis, comprising the innovative medicines business and the continuing Corporate activities and Discontinued operations include operational results from the Sandoz business.